|
|
Prepublished online as a Blood First Edition Paper on September 26, 2002; DOI 10.1182/blood-2002-06-1737.
 Previous Article | Table of Contents | Next Article 
Blood, 1 February 2003, Vol. 101, No. 3, pp. 1128-1140
NEOPLASIA
Gene expression profiling of human plasma cell differentiation
and classification of multiple myeloma based on similarities to
distinct stages of late-stage B-cell development
Fenghuang Zhan,
Erming Tian,
Klaus Bumm,
Ruston Smith,
Bart Barlogie, and
John Shaughnessy Jr
From the Donna and Donald Lambert Laboratory of Myeloma
Genetics at the Myeloma Institute for Research and Therapy, University
of Arkansas for Medical Sciences, Little Rock, AR.
To identify genes linked to normal plasma cell (PC)
differentiation and to classify multiple myeloma (MM) with respect to the expression patterns of these genes, we analyzed global mRNA expression in CD19-enriched B cells (BCs) from 7 tonsils,
CD138-enriched PCs from 11 tonsils, 31 normal bone marrow samples, and
74 MM bone marrow samples using microarrays interrogating 6800 genes. Hierarchical clustering analyses with 3288 genes clearly
segregated the 4 cell types, and chi-square and Wilcoxin rank sum tests
(P < .0005) identified 359 and 500 previously defined
and novel genes that distinguish tonsil BCs from tonsil PCs (early
differentiation genes [EDGs]), and tonsil PCs from bone marrow PCs
(late differentiation genes [LDGs]), respectively. MM as a whole was
found to have dramatically variable expression of EDGs and
LDGs, and one-way analysis of variance (ANOVA) was used to identify the
most variable EDGs (vEDGs) and LDGs (v1LDG and v2LDG). Hierarchical
cluster analysis with these genes revealed that previously defined MM
gene expression subgroups (MM1-MM4) could be linked to one of the 3 normal cell types. Clustering with 30 vEDGs revealed that 13 of 18 MM4
cases clustered with tonsil BCs (P = .000 05), whereas
14 of 15 MM3 cases clustered with tonsil PCs when using 50 v1LDG
(P = .000 008), and 14 of 20 MM2 cases clustered with
bone marrow PCs when using 50 v2LDG
(P = .000 09). MM1 showed no significant linkage with
normal cell types studied. Thus, genes whose expression is linked to
distinct transitions in late-stage B-cell differentiation can be used
to classify MM.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Anguiano, S. A. Tuchman, C. Acharya, K. Salter, C. Gasparetto, F. Zhan, M. Dhodapkar, J. Nevins, B. Barlogie, J. D. Shaughnessy Jr, et al.
Gene Expression Profiles of Tumor Biology Provide a Novel Approach to Prognosis and May Guide the Selection of Therapeutic Targets in Multiple Myeloma
J. Clin. Oncol.,
September 1, 2009;
27(25):
4197 - 4203.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Wang, G. Tricot, L. Shi, W. Xiong, Z. Zeng, H. Xu, M. Zangari, B. Barlogie, J. D. Shaughnessy Jr, and F. Zhan
RAR{alpha}2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma
Blood,
July 16, 2009;
114(3):
600 - 607.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Roccaro, A. Sacco, C. Chen, J. Runnels, X. Leleu, F. Azab, A. K. Azab, X. Jia, H. T. Ngo, M. R. Melhem, et al.
microRNA expression in the biology, prognosis, and therapy of Waldenstrom macroglobulinemia
Blood,
April 30, 2009;
113(18):
4391 - 4402.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D.-M. Shin, D. J. Shaffer, H. Wang, D. C. Roopenian, and H. C. Morse III
NOTCH Is Part of the Transcriptional Network Regulating Cell Growth and Survival in Mouse Plasmacytomas
Cancer Res.,
November 15, 2008;
68(22):
9202 - 9211.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Xiong, X. Wu, S. Starnes, S. K. Johnson, J. Haessler, S. Wang, L. Chen, B. Barlogie, J. D. Shaughnessy Jr, and F. Zhan
An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma
Blood,
November 15, 2008;
112(10):
4235 - 4246.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Wang, C. H. Lee, C. Qi, P. Tailor, J. Feng, S. Abbasi, T. Atsumi, and H. C. Morse III
IRF8 regulates B-cell lineage specification, commitment, and differentiation
Blood,
November 15, 2008;
112(10):
4028 - 4038.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-M. Hogerkorp and C. A. K. Borrebaeck
The Human CD77- B Cell Population Represents a Heterogeneous Subset of Cells Comprising Centroblasts, Centrocytes, and Plasmablasts, Prompting Phenotypical Revision
J. Immunol.,
October 1, 2006;
177(7):
4341 - 4349.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Zhan, Y. Huang, S. Colla, J. P. Stewart, I. Hanamura, S. Gupta, J. Epstein, S. Yaccoby, J. Sawyer, B. Burington, et al.
The molecular classification of multiple myeloma
Blood,
September 15, 2006;
108(6):
2020 - 2028.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Nadav, B.-Z. Katz, S. Baron, N. Cohen, E. Naparstek, and B. Geiger
The Generation and Regulation of Functional Diversity of Malignant Plasma Cells.
Cancer Res.,
September 1, 2006;
66(17):
8608 - 8616.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. B. Baughn, M. Di Liberto, K. Wu, P. L. Toogood, T. Louie, R. Gottschalk, R. Niesvizky, H. Cho, S. Ely, M. A.S. Moore, et al.
A novel orally active small molecule potently induces g1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6.
Cancer Res.,
August 1, 2006;
66(15):
7661 - 7667.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. H. Lee, M. Melchers, H. Wang, T. A. Torrey, R. Slota, C.-F. Qi, J. Y. Kim, P. Lugar, H. J. Kong, L. Farrington, et al.
Regulation of the germinal center gene program by interferon (IFN) regulatory factor 8/IFN consensus sequence-binding protein
J. Exp. Med.,
January 23, 2006;
203(1):
63 - 72.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Ely, M. Di Liberto, R. Niesvizky, L. B. Baughn, H. J. Cho, E. N. Hatada, D. M. Knowles, J. Lane, and S. Chen-Kiang
Mutually Exclusive Cyclin-Dependent Kinase 4/Cyclin D1 and Cyclin-Dependent Kinase 6/Cyclin D2 Pairing Inactivates Retinoblastoma Protein and Promotes Cell Cycle Dysregulation in Multiple Myeloma
Cancer Res.,
December 15, 2005;
65(24):
11345 - 11353.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Lotz, S. A. Mutallib, N. Oehlrich, U. Liewer, E. A. Ferreira, M. Moos, M. Hundemer, S. Schneider, S. Strand, C. Huber, et al.
Targeting Positive Regulatory Domain I-Binding Factor 1 and X Box-Binding Protein 1 Transcription Factors by Multiple Myeloma-Reactive CTL
J. Immunol.,
July 15, 2005;
175(2):
1301 - 1309.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. L. Bergsagel, W. M. Kuehl, F. Zhan, J. Sawyer, B. Barlogie, and J. Shaughnessy Jr
Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma
Blood,
July 1, 2005;
106(1):
296 - 303.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Moir, A. Malaspina, O. K. Pickeral, E. T. Donoghue, J. Vasquez, N. J. Miller, S. R. Krishnan, M. A. Planta, J. F. Turney, J. S. Justement, et al.
Decreased Survival of B Cells of HIV-viremic Patients Mediated by Altered Expression of Receptors of the TNF Superfamily
J. Exp. Med.,
September 6, 2004;
200(5):
587 - 600.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Fonseca, B. Barlogie, R. Bataille, C. Bastard, P. L. Bergsagel, M. Chesi, F. E. Davies, J. Drach, P. R. Greipp, I. R. Kirsch, et al.
Genetics and Cytogenetics of Multiple Myeloma: A Workshop Report
Cancer Res.,
February 15, 2004;
64(4):
1546 - 1558.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Heider, I. Zavrski, C. Jakob, C. Fleissner, O. Sezer, A. C. W. Zannettino, B. Pan, A. N. Farrugia, G. J. Atkins, and L. B. To
Identification and Clinical Relevance of Receptor Activator of Nuclear Factor {kappa}B Ligand Expression of Myeloma Cells
Cancer Res.,
January 15, 2004;
64(2):
773 - 775.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-L. Harousseau, J. Shaughnessy Jr., and P. Richardson
Multiple Myeloma
Hematology,
January 1, 2004;
2004(1):
237 - 256.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Tian, F. Zhan, R. Walker, E. Rasmussen, Y. Ma, B. Barlogie, and J. D. Shaughnessy Jr.
The Role of the Wnt-Signaling Antagonist DKK1 in the Development of Osteolytic Lesions in Multiple Myeloma
N. Engl. J. Med.,
December 25, 2003;
349(26):
2483 - 2494.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A. Croonquist, M. A. Linden, F. Zhao, and B. G. Van Ness
Gene profiling of a myeloma cell line reveals similarities and unique signatures among IL-6 response, N-ras-activating mutations, and coculture with bone marrow stromal cells
Blood,
October 1, 2003;
102(7):
2581 - 2592.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Shaughnessy Jr
Primer on Medical Genomics Part IX: Scientific and Clinical Applications of DNA Microarrays--Multiple Myeloma as a Disease Model
Mayo Clin. Proc.,
September 1, 2003;
78(9):
1098 - 1109.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. Tarte, F. Zhan, J. De Vos, B. Klein, and J. Shaughnessy Jr
Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation
Blood,
July 15, 2003;
102(2):
592 - 600.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K.-D. Wu, L. M. Orme, J. Shaughnessy Jr, J. Jacobson, B. Barlogie, and M. A. S. Moore
Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival
Blood,
June 15, 2003;
101(12):
4982 - 4989.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Shaughnessy, J. Jacobson, J. Sawyer, J. McCoy, A. Fassas, F. Zhan, K. Bumm, J. Epstein, E. Anaissie, S. Jagannath, et al.
Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression
Blood,
May 15, 2003;
101(10):
3849 - 3856.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
